

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) Method for treating osteoporosis in a patient, comprising:
exposing the patient to electromagnetic signals generated by pulsating,
impulse-modulated direct current, having a frequency of 1 to 30 Hz and a field strength of 1 to 20 G; and
administering Botulinum toxin to the patient, wherein the Botulinum toxin synergistically interacts with the electromagnetic signals, by inducing a non-specific immune response to further enhance [[the]] a bone density stimulation [[of]] from the exposure of the patient to the electromagnetic signals.
2. (Previously Presented) Method according to claim 1, characterised in that the modulation form is quasi-rectangular.
3. (Previously Presented) Method according to claim 1, characterised in that the frequency is approximately 5 to 15 Hz.
4. (Previously Presented) Method according to claim 1, characterised in that the field strength is approximately 10 to 15 G.
5. (Previously Presented) Method according to claim 4, characterised in that the preferred field strength is approximately 12.5 G.
6. (Previously Presented) Method according to claim 1, characterised in that the pulses are modulated.

7. (Currently Amended) Method for administering a treatment to a patient including administration of a neurotoxin, the method comprising:

providing a pharmaceutical composition comprising Botulinum toxin;
administering the Botulinum toxin to the patient intramuscularly, intravenously, or subcutaneously; and

exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional, direct current, with frequency between 1 and 30 Hz and field strength, 1 to 20 G, wherein the Botulinum toxin synergistically interacts with the electromagnetic signals, by inducing a non-specific immune response to further enhance ~~[[the]]~~ a bone density stimulation ~~[[of]]~~ from the exposure of the patient to the electromagnetic signals.

8. (Previously Presented) Method according to claim 7, characterised in that the modulation form is quasi-rectangular.

9. (Previously Presented) Method according to claim 7, characterised in that the frequency is approximately 5 to 15 Hz.

10. (Previously Presented) Method according to claim 7, characterised in that the field strength is approximately 10 to 15 G.

11. (Previously Presented) Method according to claim 10, characterised in that the field strength is approximately 12.5 G

12. (Previously Presented) Method according to claim 7, characterised in that the pulses are modulated.

13. (Previously Presented) Method according to claim 7, characterised by using a dose of Botulinum toxin Type A in the range of 20U to 600U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

14. (Previously Presented) Method according to claim 7, characterised by using Botulinum toxin Type A in the range of 50U to 300U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

15. (Previously Presented) Method according to claim 7, characterised by using Botulinum toxin Type B in the range 1U to 2000U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

16. (Previously Presented) Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 20U to 600U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

17. (Previously Presented) Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 50U to 300U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

18. (Previously Presented) Method according to claim 1, characterised by using a dose of Botulinum toxin Type B in the range 1U to 2000U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals.

19. (Currently Amended) Method according to claim 1, wherein [[the]] a combination of [[PST[®]]] exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional direct current using Pulsed Signal Therapy (PST[®]) and the

~~administration of~~ administering Botulinum toxin [[,]] enhances therapeutic benefit, including increase in bone mineral density (BMD) and a subsequent decrease in fracture risk.

20. (Currently Amended) Method according to claim 7, wherein [[the]] a combination of [[PST[®]]] exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional direct current using Pulsed Signal Therapy (PST[®]) and the ~~administration of~~ administering Botulinum toxin [[,]] enhances therapeutic benefit, including increase in bone mineral density (BMD) and a subsequent decrease in fracture risk.

REMARKS

Summary of the Final Office Action

Claims 1 – 20 stand rejected under 35 U.S.C. § 112, second paragraph, as being indefinite.

Claims 1 – 20 are indicated to be allowable if rewritten or amended to overcome the rejections under 35 U.S.C. § 112, second paragraph.

Summary of the Response to the Final Office Action

Applicant thanks the Examiner for indicating that claims 1 – 20 recite allowable subject matter.

Applicant amends claims 1, 7, 19, and 20 to place all claims in condition for allowance. Accordingly, claims 1 – 20 are presently pending.

The Rejections under 35 U.S.C. § 112, Second Paragraph

Claims 1 – 20 stand rejected under 35 U.S.C. § 112, second paragraph, as being indefinite. Specifically, independent claims 1 and 7 stand rejected for having insufficient antecedent basis for “the bone density stimulation.” Claim 19 stands rejected for having insufficient antecedent basis for “the combination of PST[®] and the administration of Botulinum toxin.” Office Action at 2.

In response, Applicant amends independent claims 1 and 7 to recite, in part, “to further enhance [[the]] a bone density stimulation [[of]] from the exposure of the patient to the electromagnetic signals.” Applicant also amends claims 19 and 20 to recite, in part, “[[the]] a combination of [[PST[®]]] exposing the patient to electromagnetic signals generated by pulsating,

pulse-modulated, unidirectional direct current using Pulsed Signal Therapy (PST®) and the
~~administration of~~ administering Botulinum toxin [[,]]” Accordingly, Applicant submits that
amended claims 1, 7, 19, and 20 comply with 35 U.S.C. § 112, second paragraph. Applicant
further submits that claims 2-6 and 8-18, which depend from claims 1 and 7 respectively, are
also allowable. Applicant respectfully submits that these amendments do not narrow the
intended scope of the claims, and therefore Applicant does not relinquish any subject matter by
the amendments. For at least these reasons, Applicant requests that the rejections of claims 1 –
20 under 35 U.S.C. § 112, second paragraph, be withdrawn.

#